• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂联素受体-1的表达与上皮性卵巢癌患者的预后

Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients.

作者信息

Li Xiahui, Yu Zhe, Fang Liping, Liu Fang, Jiang Kui

机构信息

Department of Oncology, The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).

Department of Oncology , The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (mainland).

出版信息

Med Sci Monit. 2017 Mar 30;23:1514-1521. doi: 10.12659/msm.899990.

DOI:10.12659/msm.899990
PMID:28356549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5384618/
Abstract

BACKGROUND Adiponectin receptor-1 (AdipoR1) has been reported to be associated with the risk of obesity-associated malignancies, including epithelial ovarian cancer (EOC). The aim of this study was to determine if AdipoR1 could serve as a prognosis indicator for patients with EOC. MATERIAL AND METHODS In this study, expression of AdipoR1 in 73 EOC patients consecutively admitted to our hospital was detected by immunohistochemical staining. Univariate and multivariate analyses were performed to assess the relationship between AdipoR1 expression level and progression-free survival (PFS) and overall survival (OS) rates in patients. RESULTS A relatively lower expression of AdipoR1 in the cancerous tissues was detected compared to normal ovarian tissues, but the difference was not significant (p>0.05). AdipoR1 expression level in EOC patients was negatively correlated with advanced FIGO stages in patients and tumor differentiation, but had no correlation with pathological types, presenting of ascites, shorter platinum-free interval (PFI), diabetes, preoperative and postoperative body mass index (BMI), or platelet counts (p>0.05). Moreover, patients with AdipoR1 expression had a significantly longer PFS and OS compared to the negative expression group (p<0.001). CONCLUSIONS Our findings suggest that AdipoR1 expression level in cancerous tissues might serve as an independent prognostic indicator in EOC patients and is associated with longer PFS and OS.

摘要

背景

据报道,脂联素受体-1(AdipoR1)与肥胖相关恶性肿瘤的风险有关,包括上皮性卵巢癌(EOC)。本研究的目的是确定AdipoR1是否可作为EOC患者的预后指标。

材料与方法

在本研究中,通过免疫组织化学染色检测了我院连续收治的73例EOC患者中AdipoR1的表达。进行单因素和多因素分析,以评估AdipoR1表达水平与患者无进展生存期(PFS)和总生存期(OS)率之间的关系。

结果

与正常卵巢组织相比,癌组织中AdipoR1的表达相对较低,但差异不显著(p>0.05)。EOC患者的AdipoR1表达水平与患者的国际妇产科联盟(FIGO)晚期分期和肿瘤分化呈负相关,但与病理类型、腹水情况、较短的无铂间期(PFI)、糖尿病、术前和术后体重指数(BMI)或血小板计数无关(p>0.05)。此外,与阴性表达组相比,AdipoR1表达阳性的患者的PFS和OS显著更长(p<0.001)。

结论

我们的研究结果表明,癌组织中AdipoR1的表达水平可能作为EOC患者的独立预后指标,并且与更长的PFS和OS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/ad8b88ac34fe/medscimonit-23-1514-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/437a25d238b6/medscimonit-23-1514-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/9a14b62386eb/medscimonit-23-1514-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/ad8b88ac34fe/medscimonit-23-1514-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/437a25d238b6/medscimonit-23-1514-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/9a14b62386eb/medscimonit-23-1514-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f317/5384618/ad8b88ac34fe/medscimonit-23-1514-g003.jpg

相似文献

1
Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients.脂联素受体-1的表达与上皮性卵巢癌患者的预后
Med Sci Monit. 2017 Mar 30;23:1514-1521. doi: 10.12659/msm.899990.
2
Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines.脂联素及其受体的表达在上皮性卵巢肿瘤和腹水来源的卵巢癌细胞系中发生改变。
Int J Gynecol Cancer. 2015 Mar;25(3):399-406. doi: 10.1097/IGC.0000000000000369.
3
PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.PRSS3 表达与上皮性卵巢癌的肿瘤进展和不良预后相关。
Gynecol Oncol. 2015 Jun;137(3):546-52. doi: 10.1016/j.ygyno.2015.02.022. Epub 2015 Feb 28.
4
Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.中心体蛋白55的上调与上皮性卵巢癌的不良预后和肿瘤侵袭相关。
Tumour Biol. 2016 May;37(5):6239-54. doi: 10.1007/s13277-015-4419-6. Epub 2015 Nov 28.
5
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.高迁移率族蛋白盒1在卵巢上皮性癌中的临床影响
Arch Gynecol Obstet. 2016 Mar;293(3):645-50. doi: 10.1007/s00404-015-3864-1. Epub 2015 Aug 25.
6
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.JARID1B的过表达与上皮性卵巢癌的不良预后和化疗耐药相关。
Tumour Biol. 2015 Apr;36(4):2465-72. doi: 10.1007/s13277-014-2859-z. Epub 2015 Feb 8.
7
Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.初次手术时腹水的细胞因子分析表明,肿瘤坏死因子-α和白细胞介素-6之间的相互作用可预测上皮性卵巢癌无进展生存期缩短。
Gynecol Oncol. 2015 Aug;138(2):352-7. doi: 10.1016/j.ygyno.2015.05.009. Epub 2015 May 20.
8
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.在非浆液性上皮性卵巢癌患者中,FOXM1表达与化疗耐药及不良预后显著相关。
J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.
9
Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.阿贝尔森相互作用蛋白1的上调预示上皮性卵巢癌的肿瘤进展和不良预后。
Hum Pathol. 2015 Sep;46(9):1331-40. doi: 10.1016/j.humpath.2015.05.015. Epub 2015 May 30.
10
Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.上皮性卵巢癌中polo样蛋白激酶1、P53和P21WAF1的调控异常提示预后不良。
Oncol Rep. 2015 Mar;33(3):1235-42. doi: 10.3892/or.2015.3723. Epub 2015 Jan 15.

引用本文的文献

1
The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer.选定的脂肪细胞因子在卵巢癌和子宫内膜癌中的作用。
Cells. 2023 Apr 9;12(8):1118. doi: 10.3390/cells12081118.
2
The impact of obesity and adipokines on breast and gynecologic malignancies.肥胖和脂肪细胞因子对乳腺和妇科恶性肿瘤的影响。
Ann N Y Acad Sci. 2022 Dec;1518(1):131-150. doi: 10.1111/nyas.14916. Epub 2022 Oct 27.
3
Adiponectin: A player in the pathogenesis of hormone-dependent cancers.脂联素:激素依赖性癌症发病机制中的一个参与者。

本文引用的文献

1
Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection.基于经阴道超声的高级别浆液性卵巢癌进展动态建模用于筛查和早期检测
PLoS One. 2016 Jun 3;11(6):e0156661. doi: 10.1371/journal.pone.0156661. eCollection 2016.
2
The role of adiponectin in obesity-associated female-specific carcinogenesis.脂联素在肥胖相关女性特发性致癌中的作用。
Cytokine Growth Factor Rev. 2016 Oct;31:37-48. doi: 10.1016/j.cytogfr.2016.03.014. Epub 2016 Apr 6.
3
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Front Endocrinol (Lausanne). 2022 Oct 6;13:1018515. doi: 10.3389/fendo.2022.1018515. eCollection 2022.
4
Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.卵巢癌预后因素及生物标志物的研究进展
J Cancer. 2021 May 13;12(13):3976-3996. doi: 10.7150/jca.47695. eCollection 2021.
5
Adiponectin: Role in Physiology and Pathophysiology.脂联素:在生理和病理生理中的作用
Int J Prev Med. 2020 Sep 3;11:136. doi: 10.4103/ijpvm.IJPVM_193_20. eCollection 2020.
6
Adipocytokines: Are they the Theory of Everything?脂肪细胞因子:它们是万物理论吗?
Cytokine. 2020 Sep;133:155144. doi: 10.1016/j.cyto.2020.155144. Epub 2020 Jun 16.
7
Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells.脂联素受体激动剂 AdipoRon 诱导人卵巢癌细胞凋亡和抑制增殖。
Mol Cell Biochem. 2019 Nov;461(1-2):37-46. doi: 10.1007/s11010-019-03586-9. Epub 2019 Jul 10.
8
Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk.脂肪组织、肥胖与脂联素:在激素型癌症风险中的作用。
Int J Mol Sci. 2019 Jun 12;20(12):2863. doi: 10.3390/ijms20122863.
9
The Emerging Role of Adiponectin in Female Malignancies.脂联素在女性恶性肿瘤中的新作用。
Int J Mol Sci. 2019 Apr 30;20(9):2127. doi: 10.3390/ijms20092127.
10
Mechanisms of Adiponectin Action in Fertility: An Overview from Gametogenesis to Gestation in Humans and Animal Models in Normal and Pathological Conditions.脂联素在生育力中的作用机制:正常和病理条件下人类和动物模型从配子发生到妊娠的概述。
Int J Mol Sci. 2019 Mar 27;20(7):1526. doi: 10.3390/ijms20071526.
晚期糖基化终末产物-晚期糖基化终末产物受体轴在结直肠癌中的临床意义:与乙二醛酶-I、脂联素受体表达及预后的关系
BMC Cancer. 2016 Mar 1;16:174. doi: 10.1186/s12885-016-2213-5.
4
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.卵巢透明细胞癌的潜在靶点:最新进展与未来展望综述
Cancer Cell Int. 2015 Dec 15;15:117. doi: 10.1186/s12935-015-0267-0. eCollection 2015.
5
Wnt signalling in gynaecological cancers: A future target for personalised medicine?妇科癌症中的Wnt信号传导:个性化医疗的未来靶点?
Gynecol Oncol. 2016 Feb;140(2):345-51. doi: 10.1016/j.ygyno.2015.09.085. Epub 2015 Sep 30.
6
Lesser-Known Molecules in Ovarian Carcinogenesis.卵巢癌发生中鲜为人知的分子
Biomed Res Int. 2015;2015:321740. doi: 10.1155/2015/321740. Epub 2015 Aug 3.
7
Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.顺铂类似物在复发性宫颈癌中对铂的敏感性及与顺铂的非交叉耐药性。
J Gynecol Oncol. 2015 Jul;26(3):185-92. doi: 10.3802/jgo.2015.26.3.185.
8
Exosomes: Emerging biomarkers and targets for ovarian cancer.外泌体:卵巢癌的新兴生物标志物和治疗靶点。
Cancer Lett. 2015 Oct 10;367(1):26-33. doi: 10.1016/j.canlet.2015.07.014. Epub 2015 Jul 17.
9
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.肥胖与卵巢癌女性患者的生存率:卵巢癌协会联盟的研究结果
Br J Cancer. 2015 Sep 1;113(5):817-26. doi: 10.1038/bjc.2015.245. Epub 2015 Jul 7.
10
Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines.脂联素及其受体的表达在上皮性卵巢肿瘤和腹水来源的卵巢癌细胞系中发生改变。
Int J Gynecol Cancer. 2015 Mar;25(3):399-406. doi: 10.1097/IGC.0000000000000369.